Investor Relations

Delivering value to our shareholders with utmost transparency and timely information.

At Mega Lifesciences public company limited

Investor Relations is responsible for delivering value to our shareholders by communicating all the necessary information on a regular basis.

Investment Highlights

Market leading own consumer health and pharmaceutical brands in fast growing developing markets.

Financial Performance in 1Q24

Overall operating revenue
THB mn
(Flat YoY)
Gross profit
THB mn
representing 46.8% of operating revenue
SG&A expenses
THB mn
representing 28.6% of operating revenue
Adjusted net profit
THB mn
(down by 9.5% YoY)
Reported net profit
THB mn
(up by 5.4% YoY)

Latest Documents

Read our recent and archived releases, Financial statements, Quarterly results, Presentations, Publications and One Reports.

Financial Statement
Quarter 1/2024
Download
MD&A
Quarter 1/2024
Download
Presentation and Webcast
The Opportunity Day Q1/2024
View Webcast Download
Form 56-1 One Report
Form 56-1 One Report 2023
Download
Resource Center

SET Announcements

13 May 2024
Management Discussion and Analysis Quarter 1 Ending 31 Mar 2024
Read More
13 May 2024
Financial Performance Quarter 1 (F45) (Reviewed)
Read More
13 May 2024
Financial Statement Quarter 1/2024 (Reviewed)
Read More

IR Calendar

13
Aug
2024
2Q24 earnings announcement

IR CONTACT

  • Mr. Manoj Gurbuxani (Primary contact)
  • Mr. Francis Rego
  • Ms. Sujintana Boonworapat
  • Ms. Laila Mitnoi (IR Co-ordinator)
  • Mr. Thomas Abraham
  • Mr. Vivek Dhawan
  • investor@megawecare.com
  • +66 2 769 4230